

OXFORD BIOSCIENCE PARTNERS IV LP  
 Form 4  
 January 20, 2006

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 OXFORD BIOSCIENCE  
 PARTNERS IV LP

(Last) (First) (Middle)

222 BERKELEY ST.

(Street)

BOSTON, MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 Solexa, Inc. [SLXA]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 01/18/2006

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director  
 \_\_\_ Officer (give title below)  
 \_\_\_ 10% Owner  
 \_\_\_X Other (specify below)  
 Former 10% Owner

6. Individual or Joint/Group Filing(Check Applicable Line)  
 \_\_\_ Form filed by One Reporting Person  
 \_\_\_X Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
Common	01/18/2006		J <sup>(1)</sup>	1,980,133	D \$ 0	1,035,355	D
Common	01/18/2006		J <sup>(2)</sup>	19,867	D \$ 0	10,388	I

By mRNA Fund II L.P.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
						Code	V	(A)	(D)

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
OXFORD BIOSCIENCE PARTNERS IV LP 222 BERKELEY ST. BOSTON, MA 02116				Former 10% Owner
MRNA FUND II LP 222 BERKELEY ST. BOSTON, MA 02116				Former 10% Owner

## Signatures

/s/ Jonathan J. Fleming, as general partner of the general partner of Oxford Bioscience Partners IV L.P. 01/20/2006  
 \_\_Signature of Reporting Person Date

/s/ Jonathan J. Fleming, as general partner of the general partner of mRNA Fund II L.P. 01/20/2006  
 \_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On January 18, 2006 Oxford Bioscience Partners IV L.P. ("Oxford IV") distributed an aggregate of 1,980,133 shares of the Issuer's Common Stock to its partners for no consideration. As a result of the distribution, Oxford IV no longer beneficially owns such distributed shares.
- (2) On January 18, 2006 mRNA Fund II L.P. ("mRNA") distributed an aggregate of 19,867 shares of the Issuer's Common Stock to its partners for no consideration. As a result of the distribution, mRNA no longer beneficially owns such distributed shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.